æ¥æ¬ã§ãðæ¥çš®ãåºãŸãã°ãåãã人ã®èº«è¿ã«ãã人ãã¡ã«åœ±é¿ãåã³ãŸããäŸãã°åå± äžã®ç¥ç¶æ¯ãåããã°ãã®å®¶æã«ãåŠæ ¡ã®æå¡ãçåããŠããã°ãçåŸã¿ããªã«ã âŒïžð§ðŠâïž
æ°åã³ããã¯ã¯ãã³ã¯å±éº - YouTube
äžèšã¯åç»ã®ã³ã¡ã³ãæ¬ããã®æç²ã§ããããã·ã³ãžã£ãŒãèšã£ãŠãããããããšãçŸå®ã«èµ·ããŠããããã«æããŸãã ããããããæ¬åœãªãéåžžã«ã€ããã§ãã⊠ãã¯ãèªåã ãã¯ã¯ãã³ðãæããªããã°è¯ããïŒãšèšã話ã§ã¯ãªãâŠãð§ðŠ
ãŒãŒãŒãŒãŒãŒãŒãŒãŒãŒãŒãŒãŒãŒãŒãŒãŒãŒãŒãŒãŒãŒãŒãŒãŒãŒãŒãŒãŒãŒãŒãŒãŒãŒãŒãŒãŒ
çŸåšã«ãªãã©ã«ãã¢åšäœã®ãã®ã§ãããã¡ãã¯æ¯æ¥ã¯ã¯ãã³æ¥çš®ã倧éçç£ã®ããã«ãã¡ãã¡ã§ãããŠããŸããæè¿æããã«ãªã£ãŠããããšã¯ãåããæ¬äººã ãã§ã¯ãªãããã®äººãšèº«è¿ã«æ¥ãã人ãã¡ã«åºãæªåœ±é¿ã§ããåããŠããªã人ã§ããåãã人ãšåå± ããŠãããé·æéåã空éã«ãã人ãã¡ã®ç¹ã«çæ®æ©èœã«ç°åžžãåºãŠããŸãã女æ§ãªããç°åžžççã倧éåºè¡ãåå®®ã®äžéšãè æããŠå¥ããèœã¡ããç·æ§ã¯ç²Ÿåæžå°ãªã©ãåãã人ã¯ãæµç£ãæ°å€ãå ±åãããŠããŸãã幎霢é¢ä¿ãªãæ»äº¡ãå身麻çºãæã£ãçŽåŸã«æç¡ç¶æ ã«ãªããªã©ã説æãã€ããªãåŠæ æãé çãç±ãªã©ã¯å¹Žéœ¢é¢ä¿ãªããã£ãšç¶ã人ãããŸãã
ä»ã¯ã¯ãã³ãšèšãããŠãããããã®æ³šå°ã¯ãæ£åŒã«ã¯ã¢ã¡ãªã«ã®FDA (Food and Drug Administration)ã§èªå¯ãããŠããŸãããã ããã©ãã®å£äœãæ³çã«æåã矩åä»ããããšã¯ã§ããªãã¯ããªã®ã§ãããå·æã«å§ããããŸãããããŠã¿ããªç©æ¥µçã«åãã§åãã«ãã£ãŠããŸããä»ã¯ãEUA (Emergency Use Authorization)ã䜿ã£ãŠæåãé²ããŠããã®ã§ãããããããæ£åŒèªå¯ã§ã¯ãªããŸã EUAã䜿ã£ãŠãããšããã®ã¯ãå®å šæ§ã蚌æãããŠããªããäœãèµ·ããã誰ãããããªããšããããšãªã®ã§ããEUAããããããåãããããã©ãããŒãã§ã¯ãªãããŸã æ£åŒã«GOãµã€ã³ã¯ã©ããåºããŠããªããšããããšãªã ãã§ããè£ãè¿ãã°ãæã€ã®ã¯åæã§ãã責任ã¯åããŸããããšããã®ãšåãã
æ¥æ¬ã§ãæ¥çš®ãåºãŸãã°ãåãã人ã®èº«è¿ã«ãã人ãã¡ã«åœ±é¿ãåã³ãŸããäŸãã°åå±
äžã®ç¥ç¶æ¯ãåããã°ãã®å®¶æã«ãåŠæ ¡ã®æå¡ãçåããŠããã°ãçåŸã¿ããªã«ãã©ããããŸã ãã®è©±ãã§ãã人ãããã°ãäŒããŠãã ãããèªåã ãããªããã°å®å
šããšãã話ã§ã¯ãããªããªã£ãŠããŠããŸããð âŒïžð§ðŠ
ãŒãŒãŒãŒãŒãŒãŒãŒãŒãŒãŒãŒãŒãŒãŒãŒãŒãŒãŒãŒãŒãŒãŒãŒãŒãŒãŒãŒãŒãŒãŒãŒãŒãŒãŒãŒãŒ
倧é絶æ»
ãã·ãŒã³ãæŽãããïŒ
ã¯ã¯ãã³æ¥çš®ãåãã人ã
ãå¥åº·ãªäººã
ãç
æ°ã«ããŠããçç±ãã¹ãã€ã¯ã»ã¿ã³ãã¯è³ªã¯çç©å
µåšã§ã
ã«ããŽãª : ãã€ã¯ã»ã¢ãã ã¹ãããã¥ã©ã«ã»ãã¥ãŒã¹å»çç¯çœª
倧é絶æ»
ãã·ãŒã³ãæŽãããïŒã¯ã¯ãã³æ¥çš®ãåãã人ã
ãå¥åº·ãªäººã
ãç
æ°ã«ããŠããçç±ããã¡ã€ã¶ãŒã®ææžã¯ã¯ã¯ãã³æ¥çš®ãåãã人ã
ãæææ§ç²åããæµããããšãèªããŠããŸããã¹ãã€ã¯ã»ã¿ã³ãã¯è³ªã¯çç©å
µåšã§ã
2021幎5æ3æ¥
ãã€ã¯ã»ã¢ãã ã¹
(ããã¥ã©ã«ã»ãã¥ãŒã¹ïŒã¯ã¯ãã³ã¯çç©å µåšã§ããå ·äœçã«ã¯ãã¹ãã€ã¯ã»ã¿ã³ãã¯è³ªã¯çç©æŽ»æ§å µåšã§ããã人ãã人ãžãšåºããããã«èšèšãããŠãããã¯ã¯ãã³æ¥çš®ãããŠããªã人ã«ææããããã«ã¯ã¯ãã³æ¥çš®ããã人ããäŒæããŸãã
ãã«ã»ã²ã€ããã¯ã¯ãã³ãéã¶ããã«èã䜿çšããããšãé·ãéæãã§ããããšã決ããŠå¿ããªãã§ãã ãããããããã°ã人ã ã¯èªåã®åžæã«åããŠïŒãããŠå®å šã«ã€ã³ãã©ãŒã ãã»ã³ã³ã»ã³ã(åæ)ãªãã§ïŒã¯ã¯ãã³æ¥çš®ãåããããšãã§ããŸããããŠã圌ãã¯èãå¿ èŠãšããªãããšãããããŸããã圌ãã¯åã圹å²ãæããæºåãã§ããŠããåŸé ãªäººéãæã£ãŠããŸãã
mRNAã¯ã¯ãã³ã泚å°ããã人ã ã¯ãäœãçç©å µåšå·¥å Žã«å€ããå£ãç®èïŒãããŠã¡ãªã¿ã«ç²Ÿæ¶²ïŒããæŸåºãããã¹ãã€ã¯ã»ã¿ã³ãã¯è³ªç²åãããåããåšå²ã®ãã¹ãŠã®äººã«ææãããŠããŸããã¹ãã€ã¯ã¿ã³ãã¯è³ªã¯çç©åŠçã«æŽ»æ§ã§ãããè¡æ ãåŒãèµ·ãããè³åäžãå¿èçºäœãèºå¡æ çãäžåŠçã®åœ±é¿ãåŒãèµ·ãããŸãããã¡ã€ã¶ãŒèªèº«ã®ææžã¯ããã®çŸè±¡ãã¯ã¯ãã³éçºè ã«ããç¥ãããŠããããšãæããã«ããŠããŸãã
çŸåšæããã«ãªã£ãŠããã®ã¯ãä»æ¥ã®ã¯ã¯ãã³ã¯ãã¯ã¯ãã³æ¥çš®ãæåŠãã人ã ã«ã¹ãã€ã¯ã¿ã³ãã¯è³ªçç©å µåšãåºããããã«ãèªå·±è€è£œã¯ã¯ãã³ãšããŠæ©èœããããã«æå³çã«èšèšããããšããããšã§ããåååç§åŠè äŒå ±ãæšå¹Žæžããããã«ããç§åŠè ã¯ç æ°ã®ããã«åºããã¯ã¯ãã³ã«åãçµãã§ããŸããäœãããŸããããªãå¯èœæ§ããããŸããïŒã
ããã¯ãã¯ã¯ãã³æ¥çš®ãåãã人ã ã®è¿ãã«ããã¯ã¯ãã³æ¥çš®ãåããŠããªã人ã ã§çŸåšçµéšãããŠãããã¹ãŠã®å¥åŠãªè¡æ¶²ååºå¹æã説æããŠããŸããããã«ã€ããŠã¯ãä»åŸããã«è©³ããå ±åããäºå®ã§ãã
ã°ããŒããªã¹ãã¯ãæçµè§£æ±ºçãã®èªå·±è€è£œã¯ã¯ãã³ã解ãæŸã¡ã人é¡ãå®å
šã«çµããããã€ããã§ãã
ä»æ¥ã®ç¶æ³æŽæ°ã§ã¯ãã°ããŒããªã¹ãã人é¡ãäžæãããã¹ãŠã®åœãçµããããæåéãäœååãã®äººã
ã殺ãããã«ãã©ã®ããã«å€§éè殺ã®å°çèŠæš¡ã®æ ¹çµ¶åªåã«çæããããæããã«ããŸããã³ããã¯ã¯ãã³ã¯ã人éã«å¯Ÿãããã®å€§éè殺èšç»ã®éèŠãªèŠçŽ ã§ãããããããã¯ã¯ãã³æçè«è
ãæ€é²å»ãç§åŠè
ãæ²é»ãããã§ããã ãå€ãã®äººã
ã«ã¯ã¯ãã³æ³šå°ã匷èŠããçç±ã説æããŠããŸãã
ã¹ãã€ã¯ã»ã¿ã³ãã¯è³ªã®äŒææ§ãšmRNAã¯ã¯ãã³ã«ããäœã®ã¿ã³ãã¯è³ªåæã®ãã€ãžã£ãã¯ã«ãããã°ããŒããªã¹ãã¯ããããç¹å®ã®äººå£ã®çŽ50ïŒ ããã¯ã¯ãã³æ¥çš®ãå¿ èŠãšãããã»ãšãã©ã®åœã§ãã§ã«ãã®ç®æšãéæããŠããŸãã
圌ãã¯ã人å£ã®æ®ãã®ååãåæããå¿ èŠãããããŸããããªããªãããããã®äººã ã¯ãã¹ãã€ã¯ã¿ã³ãã¯è³ªèªäœã®äŒæã§ãã¯ã¯ãã³æ¥çš®ããããããã§ããããã¯ãã»ãŒãã¹ãŠã®äººãã¹ãã€ã¯ã¿ã³ãã¯è³ªã«ææããããšãæå³ããä»å¹ŽåŸåã«ãªãªãŒã¹ãããéçåã³ãããŠã€ã«ã¹æ ªã«ããããããšãã»ãŒãã¹ãŠã®äººãéççåå¿ã®å¯èœæ§ã«åœ±é¿ãåãããããªããŸãã ïŒããã¯ãã€ããªãŒå µåšã·ã¹ãã ã§ãããïŒïŒ
ãããã£ãŠãå ç«èª¿ç¯ãæççé£ã®è¿œæ±ãé£åãå»è¬åäžã®ã¢ã¬ã«ã®ãŒå¢åŒ·ç©è³ªã®åé¿ãªã©ãéåžžã«éèŠã§ãã
ã·ã§ãªãŒã»ãã³ãããŒå士ãããã®æ¬¡ã®ãããªã¯ããã®ã¹ãã€ã¯ã¿ã³ãã¯è³ªãã¯ã¯ãã³æ¥çš®ã«ãã£ãŠã©ã®ããã«äŒéãããŠãããã«ã€ããŠã®éåžžã«éèŠãªæŠå¿µã説æããŠããŸãã
ãã³ãããŒå士ã¯ãããããŠã€ã«ã¹ç²åã®ãæåºãã§ã¯ãªããã¯ã¯ãã³ã®è£œé ã«äœ¿çšãããã¢ãããŠã€ã«ã¹ã«åºã¥ãã¹ãã€ã¯ã¿ã³ãã¯è³ªç²åã®ãææãã§ããããšã«æ³šæããŠãã ããã
Brighteon.com/5fc47f25-dab5-472e-aa50-44e19ce141af
ã³ããã¯ã¯ãã³ã«ãã£ãŠåŒãèµ·ãããã害ã®20ã®ã¡ã«ããºã ãæããã«ãããã³ãããŒå士ã®5æ8æ¥ã®ã©ã€ãã¹ããªãŒãã³ã°ã€ãã³ãããèŠéããªãã 詳现ã«ã€ããŠã¯ãwww.DrTenpenny.comãã芧ãã ããã
ä»æ¥ã®ç§ã®ç¶æ³æŽæ°ã§ã¯ãã°ããŒããªã¹ããããã人ããå¥ã®äººã«åºããããã«èšèšãããèªå·±è€è£œã¯ã¯ãã³ã«åºã¥ããææèŠæš¡ã®å€§éè殺ã§ã人éã«å¯Ÿãã眪ãæçµçã«ã©ã®ããã«å®è¡ããŠãããã説æããŸãã
ã¯ã¯ãã³ã¯ãã³ãããã¯ã§ãã ã¹ãã€ã¯ã¿ã³ãã¯è³ªã¯çç©å µåšã§ãã ãããŠãmRNAã·ã§ãããåãåã£ã人ã¯èª°ã§ããèªåã®äœãçç©å µåšå·¥å Žã«å€ããŠãä»ã®äººã«ææãããããã«æªçšãããŠããŸãã
誰ããä»ãã¹ã¯ãããã¹ããªããããã¯äºé²æ¥çš®ãåãã人ã ã§ãã 圌ãã¯ã¹ãŒããŒã¹ãã¬ãããŒã§ãã 圌ãã¯æ©ãçç©ç匟ã§ãã
ã©ãã§ãèããŠãåŠã³ãå ±æããŸãããã
Brighteon.com/a8a25cca-c179-4a1b-baac-fe60d301ab27
æ¯æ¥æ°ããããããã£ã¹ãïŒ
https://www.brighteon.com/channels/hrreport
ãŒãŒãŒãŒãŒãŒãŒãŒãŒãŒãŒãŒãŒãŒãŒãŒãŒãŒãŒãŒãŒãŒãŒãŒãŒãŒãŒãŒãŒãŒãŒãŒãŒãŒãŒãŒãŒ